BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27881823)

  • 1. Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.
    Danquah W; Meyer-Schwesinger C; Rissiek B; Pinto C; Serracant-Prat A; Amadi M; Iacenda D; Knop JH; Hammel A; Bergmann P; Schwarz N; Assunção J; Rotthier W; Haag F; Tolosa E; Bannas P; Boué-Grabot E; Magnus T; Laeremans T; Stortelers C; Koch-Nolte F
    Sci Transl Med; 2016 Nov; 8(366):366ra162. PubMed ID: 27881823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
    Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
    Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
    Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
    Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammasome activation in bovine monocytes by extracellular ATP does not require the purinergic receptor P2X7.
    Hussen J; Düvel A; Koy M; Schuberth HJ
    Dev Comp Immunol; 2012 Oct; 38(2):312-20. PubMed ID: 22728096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Antibody and Nanobody Tools for P2X7.
    Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
    Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
    Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
    Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334.
    Lord B; Ameriks MK; Wang Q; Fourgeaud L; Vliegen M; Verluyten W; Haspeslagh P; Carruthers NI; Lovenberg TW; Bonaventure P; Letavic MA; Bhattacharya A
    Eur J Pharmacol; 2015 Oct; 765():551-9. PubMed ID: 26386289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanical stress-induced interleukin-1beta expression through adenosine triphosphate/P2X7 receptor activation in human periodontal ligament cells.
    Kanjanamekanant K; Luckprom P; Pavasant P
    J Periodontal Res; 2013 Apr; 48(2):169-76. PubMed ID: 22881405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1β Release from Murine Macrophages.
    Sluyter R; Vine KL
    Mediators Inflamm; 2016; 2016():2097219. PubMed ID: 27524862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions.
    Wilmes M; Pinto Espinoza C; Ludewig P; Stabernack J; Liesz A; Nicke A; Gelderblom M; Gerloff C; Falzoni S; Tolosa E; Di Virgilio F; Rissiek B; Plesnilla N; Koch-Nolte F; Magnus T
    J Neuroinflammation; 2022 Oct; 19(1):256. PubMed ID: 36224611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of P2X7 antagonists with a focus on CNS indications.
    Rech JC; Bhattacharya A; Letavic MA; Savall BM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2X
    Yin J; Wang Y; Hu H; Li X; Xue M; Cheng W; Wang Y; Li X; Yang N; Shi Y; Yan S
    J Cell Mol Med; 2017 Nov; 21(11):2695-2710. PubMed ID: 28470940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 Receptor-Induced dye uptake into murine Macrophages.
    Pacheco PAF; Galvão RMS; Faria AFM; Von Ranke NL; Rangel MS; Ribeiro TM; Bello ML; Rodrigues CR; Ferreira VF; da Rocha DR; Faria RX
    Bioorg Med Chem; 2019 Apr; 27(8):1449-1455. PubMed ID: 30528164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release.
    Barberà-Cremades M; Baroja-Mazo A; Gomez AI; Machado F; Di Virgilio F; Pelegrín P
    FASEB J; 2012 Jul; 26(7):2951-62. PubMed ID: 22490780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
    Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
    J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
    Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
    Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,4-Naphthoquinones potently inhibiting P2X7 receptor activity.
    Faria RX; Oliveira FH; Salles JP; Oliveira AS; von Ranke NL; Bello ML; Rodrigues CR; Castro HC; Louvis AR; Martins DL; Ferreira VF
    Eur J Med Chem; 2018 Jan; 143():1361-1372. PubMed ID: 29133043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tanshinone II A sulfonate, but not tanshinone II A, acts as potent negative allosteric modulator of the human purinergic receptor P2X7.
    Kaiser M; Sobottka H; Fischer W; Schaefer M; Nörenberg W
    J Pharmacol Exp Ther; 2014 Sep; 350(3):531-42. PubMed ID: 24970925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A key role for redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human monocytes.
    Hewinson J; Moore SF; Glover C; Watts AG; MacKenzie AB
    J Immunol; 2008 Jun; 180(12):8410-20. PubMed ID: 18523309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic systemic P2X7 receptor blockade prevents experimental colitis.
    Marques CC; Castelo-Branco MT; Pacheco RG; Buongusto F; do Rosário A; Schanaider A; Coutinho-Silva R; de Souza HS
    Biochim Biophys Acta; 2014 Jan; 1842(1):65-78. PubMed ID: 24184714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.